Projects per year
Personal profile
Headline
ASSISTANT PROFESSOR | Medicine, Hematology and Medical Oncology
Biography
Rajwanth R. Veluswamy, MD, MSCR, is an Assistant Professor of Medicine, Hematology and Medical Oncology, and a board certified medical oncologist who specializes in the treatment of lung cancer and other thoracic malignancies. He completed both a clinical fellowship in Hematology and Medical Oncology and a General Medicine research fellowship at the Icahn School of Medicine at Mount Sinai. Prior to this, he completed residency in Internal Medicine at Methodist Dallas Medical Center, and a research internship at MD Anderson Cancer Center in Houston. He earned his M.D. from the University of Szeged and a Masters of Science in Clinical Research at Mount Sinai. Dr. Veluswamy’s research focuses on understanding the factors responsible for clinical outcomes in lung cancer patients, from patterns of care to differences in therapeutic drug efficacy. He has published extensively and presented his research at international meetings where he has received numerous merit awards. He received a prestigious ASCO Young Investigator Award in recognition and support of his research during fellowship. As a faculty member at Mount Sinai, he uses novel research methods to investigate complex mechanisms involved in cancer and its treatment, especially in molecular therapy and immunotherapy. Dr. Veluswamy’s clinical interest is to provide personalized treatment that best fits each patient. He collaborates with a multidisciplinary team of experts and scientists that are highly active in the treatment and research of thoracic malignancies. He is dedicated to providing compassionate care to improve the lives of his patients and their families.
Fingerprint
Dive into the research topics where Rajwanth Veluswamy is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 3 Active
-
Outcomes Following SBRT vs. IMRT and 3DCRT for Older Patients with Stage IIA Node-Negative Non-Small Cell Lung Cancer > 5 cm
Tran, J. H., Mhango, G., Park, H. S., Marshall, D. C., Rosenzweig, K. E., Wang, Q., Wisnivesky, J. P. & Veluswamy, R. R., Jan 2023, In: Clinical Lung Cancer. 24, 1, p. e9-e18Research output: Contribution to journal › Article › peer-review
-
Adverse Events Following Limited Resection versus Stereotactic Body Radiation Therapy for Early Stage Lung Cancer
Wang, Q., Stone, K., Kern, J. A., Slatore, C. G., Swanson, S., Blackstock, W., Khan, R. S., Smith, C. B., Veluswamy, R. R., Chidel, M. & Wisnivesky, J. P., 1 Dec 2022, In: Annals of the American Thoracic Society. 19, 12, p. 2053-2061 9 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
Immunotherapy Outcomes in Individuals with Non-Small Cell Lung Cancer and Poor Performance Status
Veluswamy, R., Hu, L., Smith, C., Ji, J., Wang, X., Wisnivesky, J., Morillo, J. & Kale, M. S., 1 Apr 2022, In: JNCI Cancer Spectrum. 6, 2, pkac013.Research output: Contribution to journal › Article › peer-review
Open Access -
Modulation of chemoimmunotherapy efficacy in non-small cell lung cancer by sex and histology: a real-world, patient-level analysis
Tuminello, S., Alpert, N., Veluswamy, R. R., Kumar, A., Gomez, J. E., Flores, R. & Taioli, E., Dec 2022, In: BMC Cancer. 22, 1, 80.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Optimizing the use of adjuvant chemotherapy in non-small cell lung cancer patients with comorbidities
Bailey, S., Wang, Q., Kong, C. Y., Stone, K., Veluswamy, R., Bates, S. E., Smith, C. B., Wisnivesky, J. P. & Sigel, K., Aug 2022, In: Current Problems in Cancer. 46, 4, 100867.Research output: Contribution to journal › Article › peer-review
Press/Media
-
BerGenBio ASA: Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations
11/03/23
1 item of Media coverage
Press/Media
-
-BERGENBIO ANNOUNCES FIRST PATIENT DOSED IN PHASE 1B/2A TRIAL EVALUATING BEMCENTINIB IN 1ST LINE NON-SMALL CELL LUNG CANCER WITH STK11 MUTATIONS
10/03/23
2 items of Media coverage
Press/Media
-
BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations
9/03/23
73 items of Media coverage
Press/Media
-
Bergenbio Announces First Patient Dosed In Phase 1B/2A Trial Evaluating Bemcentinib In 1St Line Non-Small Cell Lung Cancer With STK11 Mutations
9/03/23
32 items of Media coverage
Press/Media
-
Tisch Cancer Institute Researchers Describe New Findings in Non-Small Cell Lung Cancer (Real-World longitudinal practice patterns in the use of PD-1 and PD-L1 inhibitors as First-Line therapy in patients with Non-Small cell lung cancer in the ...)
Fred Hirsch, Fred Hirsch, Rajwanth Veluswamy & Emanuela Taioli
6/12/22
1 item of Media coverage
Press/Media